Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma.

Li T, Deng Y, Shi Y, Tian R, Chen Y, Zou L, Kazi JU, Rönnstrand L, Feng B, Chan SO, Chan WY, Sun J, Zhao H.

Oncogene. 2018 Jul 16. doi: 10.1038/s41388-018-0397-7. [Epub ahead of print]

PMID:
30013190
2.

Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression.

Shah K, Moharram SA, Kazi JU.

Clin Epigenetics. 2018 Jun 19;10:83. doi: 10.1186/s13148-018-0516-x. eCollection 2018.

3.

De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.

Hyrenius-Wittsten A, Pilheden M, Sturesson H, Hansson J, Walsh MP, Song G, Kazi JU, Liu J, Ramakrishan R, Garcia-Ruiz C, Nance S, Gupta P, Zhang J, Rönnstrand L, Hultquist A, Downing JR, Lindkvist-Petersson K, Paulsson K, Järås M, Gruber TA, Ma J, Hagström-Andersson AK.

Nat Commun. 2018 May 2;9(1):1770. doi: 10.1038/s41467-018-04180-1.

4.

SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation.

Rupar K, Moharram SA, Kazi JU, Rönnstrand L.

Sci Rep. 2018 Apr 23;8(1):6405. doi: 10.1038/s41598-018-24743-y.

5.

T-cell Acute Lymphoblastic Leukemia Cells Display Activation of Different Survival Pathways.

Moharram SA, Shah K, Kazi JU.

J Cancer. 2017 Nov 6;8(19):4124. doi: 10.7150/jca.21725. eCollection 2017.

6.

The Src family kinase LCK cooperates with oncogenic FLT3/ITD in cellular transformation.

Marhäll A, Kazi JU, Rönnstrand L.

Sci Rep. 2017 Oct 23;7(1):13734. doi: 10.1038/s41598-017-14033-4.

7.

Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia.

Moharram SA, Shah K, Khanum F, Marhäll A, Gazi M, Kazi JU.

Cancer Lett. 2017 Oct 1;405:73-78. doi: 10.1016/j.canlet.2017.07.019. Epub 2017 Jul 26.

PMID:
28756008
8.

KITD816V Induces SRC-Mediated Tyrosine Phosphorylation of MITF and Altered Transcription Program in Melanoma.

Phung B, Kazi JU, Lundby A, Bergsteinsdottir K, Sun J, Goding CR, Jönsson G, Olsen JV, Steingrímsson E, Rönnstrand L.

Mol Cancer Res. 2017 Sep;15(9):1265-1274. doi: 10.1158/1541-7786.MCR-17-0149. Epub 2017 Jun 5.

9.

Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD.

Kazi JU, Chougule RA, Li T, Su X, Moharram SA, Rupar K, Marhäll A, Gazi M, Sun J, Zhao H, Rönnstrand L.

Cell Mol Life Sci. 2017 Jul;74(14):2679-2688. doi: 10.1007/s00018-017-2494-0. Epub 2017 Mar 7.

10.

The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).

Gazi M, Moharram SA, Marhäll A, Kazi JU.

Cancer Lett. 2017 Apr 28;392:9-16. doi: 10.1016/j.canlet.2017.01.035. Epub 2017 Feb 1.

PMID:
28159681
11.

ABL2 suppresses FLT3-ITD-induced cell proliferation through negative regulation of AKT signaling.

Kazi JU, Rupar K, Marhäll A, Moharram SA, Khanum F, Shah K, Gazi M, Nagaraj SR, Sun J, Chougule RA, Rönnstrand L.

Oncotarget. 2017 Feb 14;8(7):12194-12202. doi: 10.18632/oncotarget.14577.

12.

Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis.

Ke H, Kazi JU, Zhao H, Sun J.

Cell Biosci. 2016 Oct 18;6:55. eCollection 2016. Review.

13.

Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling.

Moharram SA, Chougule RA, Su X, Li T, Sun J, Zhao H, Rönnstrand L, Kazi JU.

Oncotarget. 2016 Sep 6;7(36):57770-57782. doi: 10.18632/oncotarget.10760.

14.

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.

Lindblad O, Cordero E, Puissant A, Macaulay L, Ramos A, Kabir NN, Sun J, Vallon-Christersson J, Haraldsson K, Hemann MT, Borg Å, Levander F, Stegmaier K, Pietras K, Rönnstrand L, Kazi JU.

Oncogene. 2016 Sep 29;35(39):5119-31. doi: 10.1038/onc.2016.41. Epub 2016 Mar 21.

15.

Expression of GADS enhances FLT3-induced mitogenic signaling.

Chougule RA, Cordero E, Moharram SA, Pietras K, Rönnstrand L, Kazi JU.

Oncotarget. 2016 Mar 22;7(12):14112-24. doi: 10.18632/oncotarget.7415.

16.

HIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells.

Alam MW, Persson CU, Reinbothe S, Kazi JU, Rönnstrand L, Wigerup C, Ditzel HJ, Lykkesfeldt AE, Påhlman S, Jögi A.

Oncotarget. 2016 Mar 8;7(10):11238-50. doi: 10.18632/oncotarget.7167.

17.

FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.

Chougule RA, Kazi JU, Rönnstrand L.

Oncotarget. 2016 Mar 1;7(9):9964-74. doi: 10.18632/oncotarget.7128.

18.

The role of HOXB2 and HOXB3 in acute myeloid leukemia.

Lindblad O, Chougule RA, Moharram SA, Kabir NN, Sun J, Kazi JU, Rönnstrand L.

Biochem Biophys Res Commun. 2015 Nov 27;467(4):742-7. doi: 10.1016/j.bbrc.2015.10.071. Epub 2015 Oct 22.

PMID:
26482852
19.

Brain-Expressed X-linked (BEX) proteins in human cancers.

Kazi JU, Kabir NN, Rönnstrand L.

Biochim Biophys Acta. 2015 Dec;1856(2):226-33. doi: 10.1016/j.bbcan.2015.09.001. Epub 2015 Sep 25. Review.

PMID:
26408910
20.

The Phosphatases STS1 and STS2 Regulate Hematopoietic Stem and Progenitor Cell Fitness.

Zhang J, Vakhrusheva O, Bandi SR, Demirel Ö, Kazi JU, Fernandes RG, Jakobi K, Eichler A, Rönnstrand L, Rieger MA, Carpino N, Serve H, Brandts CH.

Stem Cell Reports. 2015 Oct 13;5(4):633-46. doi: 10.1016/j.stemcr.2015.08.006. Epub 2015 Sep 10.

21.

BEX1 acts as a tumor suppressor in acute myeloid leukemia.

Lindblad O, Li T, Su X, Sun J, Kabir NN, Levander F, Zhao H, Lu G, Rönnstrand L, Kazi JU.

Oncotarget. 2015 Aug 28;6(25):21395-405.

22.

PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner.

Lindblad O, Kazi JU, Rönnstrand L, Sun J.

Cell Mol Life Sci. 2015 Nov;72(22):4399-407. doi: 10.1007/s00018-015-1944-9. Epub 2015 Jun 4.

PMID:
26040420
23.

Role of SRC-like adaptor protein (SLAP) in immune and malignant cell signaling.

Kazi JU, Kabir NN, Rönnstrand L.

Cell Mol Life Sci. 2015 Jul;72(13):2535-44. doi: 10.1007/s00018-015-1882-6. Epub 2015 Mar 13. Review.

PMID:
25772501
24.

The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.

Agarwal S, Kazi JU, Mohlin S, Påhlman S, Rönnstrand L.

Oncogene. 2015 Aug 27;34(35):4581-90. doi: 10.1038/onc.2014.383. Epub 2014 Dec 1.

PMID:
25435369
25.

SOCS6 is a selective suppressor of receptor tyrosine kinase signaling.

Kabir NN, Sun J, Rönnstrand L, Kazi JU.

Tumour Biol. 2014 Nov;35(11):10581-9. doi: 10.1007/s13277-014-2542-4. Epub 2014 Aug 30. Review.

PMID:
25172101
26.

Keratin 19 expression correlates with poor prognosis in breast cancer.

Kabir NN, Rönnstrand L, Kazi JU.

Mol Biol Rep. 2014 Dec;41(12):7729-35. doi: 10.1007/s11033-014-3684-6. Epub 2014 Aug 26.

PMID:
25156534
27.

SOCS proteins in regulation of receptor tyrosine kinase signaling.

Kazi JU, Kabir NN, Flores-Morales A, Rönnstrand L.

Cell Mol Life Sci. 2014 Sep;71(17):3297-310. doi: 10.1007/s00018-014-1619-y. Epub 2014 Apr 5. Review.

PMID:
24705897
28.

SYK is a critical regulator of FLT3 in acute myeloid leukemia.

Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil CF, Mehta S, Du J, Kazi JU, Luciano F, Rönnstrand L, Kung AL, Aster JC, Galinsky I, Stone RM, DeAngelo DJ, Hemann MT, Stegmaier K.

Cancer Cell. 2014 Feb 10;25(2):226-42. doi: 10.1016/j.ccr.2014.01.022.

29.

Grb10 is a dual regulator of receptor tyrosine kinase signaling.

Kabir NN, Kazi JU.

Mol Biol Rep. 2014;41(4):1985-92. doi: 10.1007/s11033-014-3046-4. Epub 2014 Jan 14. Review.

PMID:
24420853
30.

Src-like-adaptor protein (SLAP) differentially regulates normal and oncogenic c-Kit signaling.

Kazi JU, Agarwal S, Sun J, Bracco E, Rönnstrand L.

J Cell Sci. 2014 Feb 1;127(Pt 3):653-62. doi: 10.1242/jcs.140590. Epub 2013 Nov 27. Erratum in: J Cell Sci. 2014 May 15;127(Pt 10):2376.

31.

The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner.

Sun J, Mohlin S, Lundby A, Kazi JU, Hellman U, Påhlman S, Olsen JV, Rönnstrand L.

Oncogene. 2014 Nov 13;33(46):5360-9. doi: 10.1038/onc.2013.479. Epub 2013 Nov 11.

PMID:
24213578
32.

Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.

Kazi JU, Kabir NN, Rönnstrand L.

Med Oncol. 2013 Dec;30(4):757. doi: 10.1007/s12032-013-0757-7. Epub 2013 Oct 31. Review.

PMID:
24174318
33.

The basic helix-loop-helix (bHLH) proteins in breast cancer progression.

Kabir NN, Rönnstrand L, Kazi JU.

Med Oncol. 2013;30(3):666. doi: 10.1007/s12032-013-0666-9. Epub 2013 Jul 23. No abstract available.

PMID:
23877873
34.

Phosphorylation of the activation loop tyrosine 823 in c-Kit is crucial for cell survival and proliferation.

Agarwal S, Kazi JU, Rönnstrand L.

J Biol Chem. 2013 Aug 2;288(31):22460-8. doi: 10.1074/jbc.M113.474072. Epub 2013 Jun 26.

35.

The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling.

Kazi JU, Vaapil M, Agarwal S, Bracco E, Påhlman S, Rönnstrand L.

Cell Signal. 2013 Sep;25(9):1852-60. doi: 10.1016/j.cellsig.2013.05.016. Epub 2013 May 21.

PMID:
23707526
36.

Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling.

Kazi JU, Rönnstrand L.

Mol Oncol. 2013 Jun;7(3):693-703. doi: 10.1016/j.molonc.2013.02.020. Epub 2013 Mar 19.

37.

The presence or absence of IL-3 during long-term culture of Flt3-ITD and c-Kit-D816V expressing Ba/F3 cells influences signaling outcome.

Kazi JU, Sun J, Rönnstrand L.

Exp Hematol. 2013 Jul;41(7):585-7. doi: 10.1016/j.exphem.2013.03.005. Epub 2013 Mar 22. No abstract available.

PMID:
23528808
38.

Deregulation of protein phosphatase expression in acute myeloid leukemia.

Kabir NN, Rönnstrand L, Kazi JU.

Med Oncol. 2013 Jun;30(2):517. doi: 10.1007/s12032-013-0517-8. Epub 2013 Feb 26.

PMID:
23440723
39.

Protein kinase C expression is deregulated in chronic lymphocytic leukemia.

Kabir NN, Rönnstrand L, Kazi JU.

Leuk Lymphoma. 2013 Oct;54(10):2288-90. doi: 10.3109/10428194.2013.769220. Epub 2013 Feb 16. No abstract available.

PMID:
23343179
40.

FLT3 mutations in patients with childhood acute lymphoblastic leukemia (ALL).

Kabir NN, Rönnstrand L, Kazi JU.

Med Oncol. 2013 Mar;30(1):462. doi: 10.1007/s12032-013-0462-6. Epub 2013 Jan 19. No abstract available.

PMID:
23335073
41.

Selective mutation in ATP-binding site reduces affinity of drug to the kinase: a possible mechanism of chemo-resistance.

Kabir NN, Kazi JU.

Med Oncol. 2013 Mar;30(1):448. doi: 10.1007/s12032-012-0448-9. Epub 2013 Jan 10. No abstract available.

PMID:
23307256
42.

Src-Like adaptor protein (SLAP) binds to the receptor tyrosine kinase Flt3 and modulates receptor stability and downstream signaling.

Kazi JU, Rönnstrand L.

PLoS One. 2012;7(12):e53509. doi: 10.1371/journal.pone.0053509. Epub 2012 Dec 31.

43.

FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia.

Kazi JU, Rönnstrand L.

Mol Oncol. 2013 Jun;7(3):402-18. doi: 10.1016/j.molonc.2012.11.003. Epub 2012 Nov 29.

44.

Suppressor of cytokine signaling 6 (SOCS6) negatively regulates Flt3 signal transduction through direct binding to phosphorylated tyrosines 591 and 919 of Flt3.

Kazi JU, Sun J, Phung B, Zadjali F, Flores-Morales A, Rönnstrand L.

J Biol Chem. 2012 Oct 19;287(43):36509-17. doi: 10.1074/jbc.M112.376111. Epub 2012 Sep 5.

45.

Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3.

Lin DC, Yin T, Koren-Michowitz M, Ding LW, Gueller S, Gery S, Tabayashi T, Bergholz U, Kazi JU, Rönnstrand L, Stocking C, Koeffler HP.

Blood. 2012 Oct 18;120(16):3310-7. doi: 10.1182/blood-2011-10-388611. Epub 2012 Aug 31.

46.

Comparative analysis of human and bovine protein kinases reveals unique relationship and functional diversity.

Kabir NN, Kazi JU.

Genet Mol Biol. 2011 Oct;34(4):587-91. doi: 10.1590/S1415-47572011005000035. Epub 2011 Oct 1.

47.

Maximum likelihood analysis of mammalian p53 indicates the presence of positively selected sites and higher tumorigenic mutations in purifying sites.

Khan MM, Rydén AM, Chowdhury MS, Hasan MA, Kazi JU.

Gene. 2011 Sep 1;483(1-2):29-35. doi: 10.1016/j.gene.2011.05.011. Epub 2011 May 24.

PMID:
21640173
48.

Visualization of the melanosome transfer-inhibition in a mouse epidermal cell co-culture model.

Kim HJ, Kazi JU, Lee YR, Nguyen DH, Lee HB, Shin JH, Soh JW, Kim EK.

Int J Mol Med. 2010 Feb;25(2):249-53.

PMID:
20043134
49.
50.

Bioinformatic prediction and analysis of eukaryotic protein kinases in the rat genome.

Kazi JU, Kabir NN, Soh JW.

Gene. 2008 Feb 29;410(1):147-53. doi: 10.1016/j.gene.2007.12.003. Epub 2007 Dec 14.

PMID:
18201844

Supplemental Content

Support Center